share_log

中国医药(600056.SH):胞磷胆碱钠注射液通过仿制药一致性评价

China Meheco Group (600056.SH): Phosphorylcholine Sodium Injection passed the generic drug consistency evaluation.

Gelonghui Finance ·  Nov 29, 2024 17:04

Glory Holdings reported on November 29 that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received three "Pharmaceutical Supplement Application Approval Notices" approved and issued by the National Medical Products Administration for sodium cytidine diphosphate injection, which has passed the consistency evaluation of quality and efficacy for generic drugs. Sodium cytidine diphosphate injection is a drug that improves cellular metabolism and is used for consciousness disorders after acute cranial trauma and brain surgery.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment